Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
NCT06975150
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
105
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
DRUG:
HK-660S 100mg
DRUG:
HK-660S 200mg
DRUG:
Placebo
Sponsor
CuromeBiosciences